Business Wire

Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin

Share

Reinforcing its commitment to advancing dermatology for every skin story, Galderma announced today the formation of a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives through focusing on three key pillars of research, innovation and engagement that play a key role in improving the broad understanding and management of sensitive skin. Comprised of 13 experts from across the world, the group will have representation from diverse geographies including China, Brazil, the Philippines, Germany, France, Australia, Italy and the United States (U.S.).

 

“We want people to feel in control of their skin, and this is especially important for those who have skin conditions that are often misunderstood – like sensitive skin.
We’re delighted to bring together such an esteemed group of experts from around the world who will collaborate to propose and implement research, innovation and educational projects
to advance the science of sensitive skin and bring positive changes to the whole community.”

 

WALTER GEIGER
CONSUMER CARE GLOBAL BUSINESS UNIT HEAD, GALDERMA

 

Sensitive skin is a complex and often interconnected condition, requiring personalized care and products specifically designed for it. More than seventy percent of people worldwide diagnose themselves as having sensitive skin, which can negatively impact quality of life and leave them feeling frustrated and looking for better solutions.i There is a need for science-backed guidance and advice on how to identify and care for sensitive skin of all kinds, to help improve the overall quality of sensitive skin.

The Sensitive Skincare Faculty will focus on three core pillars of activities:

  • Research – expanding the understanding of sensitive skin by filling evidence gaps and advancing in emerging areas
  • Innovation – inspiring the development of new solutions to improve diagnosis and care
  • Engagement – enhancing the knowledge of healthcare professionals to shape the future of best practice

In partnership with the Department of Dermatology at the George Washington University School of Medicine and Health Sciences, two grants have been awarded to accelerate the mission of the Sensitive Skincare Faculty. The first will establish a Galderma Sensitive Skin Translational Research Fellowship Program over five years to support medical students interested in expanding their research skill set into sensitive skin. The second project, the Galderma Skin Research Acceleration Fund, will span two years and look specifically at establishing a standard definition of sensitive skin.

 

“Our goal is to transform the science of sensitive skin into actionable insights and practical advice
that will empower everyone – from consumers and patients to healthcare professionals – to make positive strides forward.
We’re bringing together the latest information backed by science and making it available and accessible to everyone who needs it.”

 

PROFESSOR ADAM FRIEDMAN
CO-CHAIR, SENSITIVE SKINCARE FACULTY,
PROFESSOR AND CHAIR OF DERMATOLOGY,
THE GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES

 

Faculty members include Adam Friedman (co-chair, U.S.), Giovanni Pellacani (Italy), Martina Kerscher (Germany), Aaron Farberg (U.S.), Flávia Alvim Sant’Anna Addor (Brazil), Belinda Welsh (Australia), Yan Wu (China), Flordeliz Abad-Casintahan (Philippines), Adelaide Hebert (U.S.), Xiang Leihong (China), Laurent Misery (France), Joachim Fluhr (Germany) and Leona Yip (Australia).

The faculty’s inaugural meeting took place at the European Academy of Dermatology and Venereology congress in Milan, where members also participated in a Galderma-sponsored symposium on sensitive skin insights and management approaches.

About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:
iChen W, Dai R, Li L. The prevalence of self‐declared sensitive skin: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2020 Aug;34(8):1779-88.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Tracy Krumme
Global Head of Investor Relations
investors@galderma.com
+1-817-961-5530

Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41

Sébastien Cros
Corporate Communications Director
Sebastien.cros@galderma.com
+41 79 529 59 85

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aktana and Envision Pharma Group Partner to Help Medical Affairs Navigate the Evolving Physician Engagement Landscape27.9.2022 14:33:00 EEST | Press release

Aktana, the leader in intelligent customer engagement for the life sciences industry, and Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs, announce a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange. By bringing together their extensive technical and industry expertise, Envision and Aktana offer life science companies the ability to enable their medical science liaisons (MSLs) to address HCP demands for personalized, scientifically relevant content and coordinated omnichannel engagement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005291/en/ Despite the industry’s separation between commercial and medical teams, today’s HCPs expect MSLs to operate with a holistic view of their engagement with the product. While many life sciences companies have already started equi

FourKites Announces $10M Strategic Investment from Mitsui & Co. to Transform Supply Chains in Asia-Pacific27.9.2022 14:30:00 EEST | Press release

Leading supply chain visibility company FourKites today announces a $10M investment from Mitsui & Co., Ltd. to expand FourKites’ offerings across the APAC region. This investment encompasses the first phase in an ongoing strategic relationship between FourKites and Mitsui, which the two companies intend to formalise by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005141/en/ FourKites Announces $10M Strategic Investment from Mitsui & Co. to Transform Supply Chains in Asia-Pacific (Graphic: Business Wire) Mitsui’s investment in FourKites is the culmination of a yearlong effort between the two companies, which included Mitsui’s extensive due diligence of the supply chain visibility landscape. Given FourKites’ market-leading offerings and proven track record in the region, Mitsui is planning to invest significant resources to expand FourKites’ coverage in APAC, including sales, customer service, oper

Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients27.9.2022 14:00:00 EEST | Press release

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities. Forge’s plasmid manufacturing services encompass three grades to accommodate a phase-appropriate approach: Research-Grade, suitable for discovery, research and development; GMP-Pathway, suitable for early-stage clinical trial cGMP AAV manufacturing, and cGMP, suitable for late-stage clinical and commercial cGMP manufacturing. Forge’s plasmid production services utilize single-use systems that seamlessly integrate into the Company’s platform AAV manufacturing process, allowing continuity of manufacturing for clients and streamlined vendor management. Research-Grade and GMP-Pathway plasmid grades are currently available,

DOQMIND Announces Peter Hulsmans as CEO27.9.2022 14:00:00 EEST | Press release

DOQMIND (www.DOQMIND.com), a leading label and artwork management technology provider, announced today that Peter Hulsmans has been appointed CEO. With more than 20 years of label and artwork management leadership experience, Hulsmans brings a high-growth, customer-focused mindset to DOQMIND. “Peter’s experience and extensive industry knowledge make him the right person to build momentum and drive DOQMIND’s aggressive expansion plans,” said Ignace Cosaert, a board member of Athena Graphics, DOQMIND’s founding company. “Peter is known in the industry as someone who always delivers on his customer commitments, aligned with Athena’s reputation for delivering high-quality prepress services since 1991. He will be an excellent steward of our values, products, and brand portfolio.” DOQMIND has been providing label and artwork management technology to some of the most well-known brands for the last 15 years as part of Athena’s product portfolio. Its growth has positioned the company to spin of

Latest Blue Shift Report From Arthur D. Little Delivers Realistic View of the Metaverse27.9.2022 13:26:00 EEST | Press release

Arthur D. Little (ADL) has published The Metaverse, beyond fantasy, the latest in a series of new reports from the company running under the ‘Blue Shift’ banner, which explore the impact of new technologies on business, society and humans. The Metaverse, Beyond Fantasy looks beyond the hype and delivers a realistic picture of the Metaverse for businesses, focusing in particular on the technologies necessary to enable it. While the Metaverse is not a new concept, the past few years have seen a rapid acceleration of both development and adoption, driven by the convergence of three industries: gaming; collaboration and productivity tools; and social media and networks. Yet while the size of the Metaverse market is difficult to estimate, the report emphasizes that companies should not underestimate its potential importance to their business. The report looks at the key enabling technologies of the Metaverse, including artificial intelligence (AI), Internet of Things (IoT) and blockchain, a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom